SPOTLIGHT: Court bows out of trade dispute

In a closely watched trial, the European Court of Justice has declared that it has no jurisdiction to make a ruling in a case involving parallel trading. The case centers on GlaxoSmithKline's efforts to block parallel traders who buy drugs at low prices in some European countries and resell them in countries where prices are higher. Experts say the decision will leave the parallel trading market in a legal limbo for years to come. Story

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.